Physician profile
Jay J Dave
NPI 1215159488
$161,058.97
in general payments reported to CMS, 2019-2025
66 companies · $3,717 in 2025
The $3,717 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $24K · 2021: $37K · 2022: $34K · 2023: $6,316 · 2024: $16K · 2025: $3,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,761 · Travel and Lodging: $770 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,410.00 |
| Food and Beverage | $9,761.34 |
| Travel and Lodging | $770.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $59,591.47 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $22,614.36 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceuticals, INC. | $21,358.84 | 2021 | |
| Tg Therapeutics, INC. | $13,231.56 | 2023-2024 | |
| Allergan, INC. | $9,623.83 | 2019-2022 | |
| Genzyme Corporation | $8,975.59 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,223.12 | 2022 | |
| Acorda Therapeutics, INC | $5,160.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,512.65 | 2019-2025 | |
| Emd Serono, INC. | $1,085.47 | 2019-2025 | Mavenclad |
| Celgene Corporation | $801.43 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $759.50 | 2019-2021 | |
| Eisai INC. | $658.32 | 2019-2025 | |
| Lundbeck LLC | $628.45 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $558.97 | 2019-2025 | Aimovig, Uplizna |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $523.15 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Pfizer INC. | $520.79 | 2023-2025 | |
| Genentech USA, INC. | $513.24 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| E.R. Squibb & Sons, L.L.C. | $493.46 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $468.83 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $359.60 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Acadia Pharmaceuticals INC | $321.47 | 2019-2025 | Nuplazid |
| Horizon Therapeutics Plc | $296.52 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $291.53 | 2019-2025 | Ultomiris |
| Ucb, INC. | $272.01 | 2019-2025 | Rystiggo, Briviact |
| Sunovion Pharmaceuticals INC. | $258.60 | 2019-2022 | |
| Harmony Biosciences LLC | $186.16 | 2024 | |
| Supernus Pharmaceuticals, INC. | $184.95 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $176.00 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Ipsen Biopharmaceuticals, INC | $155.11 | 2019-2023 | Dysport |
| Avanir Pharmaceuticals, INC. | $154.55 | 2019-2022 | |
| Argenx US, INC. | $141.38 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $132.59 | 2023-2025 | Valtoco |
| Tanabe Pharma America, INC. | $127.43 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $125.54 | 2020-2024 | Acthar |
| Csl Behring | $120.34 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $119.68 | 2023-2025 | Rexulti, Nuedexta |
| Adamas Pharmaceuticals, INC. | $116.78 | 2019-2021 | |
| Grifols USA, LLC | $84.69 | 2021-2025 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $76.11 | 2022 | |
| Livanova USA, INC. | $75.57 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Abbott Laboratories | $68.92 | 2023-2024 | Proclaim, Infinity, Penta |
| Kyowa Kirin, INC. | $63.26 | 2020-2023 | Nourianz |
| Scilex Pharmaceuticals INC. | $61.64 | 2020-2023 | Ztlido |
| Janssen Biotech, INC. | $60.21 | 2025 | |
| Sumitomo Pharma America, INC. | $59.48 | 2023-2024 | Aptiom |
| Revance Therapeutics, INC. | $58.55 | 2024 | Daxxify |
| Catalyst Pharmaceuticals, INC. | $53.08 | 2023-2025 | Firdapse |
| Boston Scientific Corporation | $51.13 | 2024-2025 | General - Dbs |
| Vanda Pharmaceuticals INC. | $50.59 | 2024-2025 | Ponvory |
| Life Molecular Imaging LTD | $48.22 | 2025 | Neuraceq |
| Insightec,INC | $44.68 | 2023-2025 | Exablate |
| Ge Healthcare | $43.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.97 | 2025 | Hyqvia |
| Ani Pharmaceuticals, INC. | $33.41 | 2025 | Purified Cortrophin Gel |
| Merz North America, INC. | $33.02 | 2019-2020 | |
| Sk Life Science, INC. | $29.90 | 2025 | |
| Mallinckrodt Enterprises LLC | $26.71 | 2019 | |
| Averitas Pharma INC. | $26.37 | 2025 | Qutenza |
| Resmed Corp | $22.97 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.71 | 2025 | |
| Medtronic, INC. | $20.96 | 2021 | |
| Cycle Pharmaceuticals INC | $20.34 | 2025 | Tascenso Odt |
| Chiesi USA, INC. | $19.05 | 2025 | Elfabrio |
| Upsher-Smith Laboratories LLC | $11.08 | 2020 | |
| Zogenix INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.